the aid library

LIST OPTIONS

Filter

2955

Sort by:

Direction:

Download (171)

View PDF (329)

Controlled clinical trails in Tuberculosis

A. Jindani, A. Nunn, D. A. Enarson International Union Against Tuberculosis and Lung Disease (2004)

A Guide For Multicentre Trials in High-Burden Countries

Download (167)

View PDF (307)

European Drug Report 2019: trends and developments.

European Monitoring Centre for Drugs and Drug Addiction European Union (2019) C1

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ... more

Download (87)

View PDF (545)

Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms

C. Chilvers, M. Dewey, K. Fielding, et al. (2001) CC

BMJ 2001;322:1–5

Download (480)

View PDF (1030)

Instruksi Presiden Republik Indonesia Nomor 3 tahun 2002 tentang Penanggulangan Penyalahgunaan dan Peredaran Gelap Narkotika, Psikotropika, Prekursor dan Zat Adiktif Lainnya

President of the Republic of Indonesia (2002) C1

Instruction of the President of the Republic of Indonesia No. 3 of 2002 concerning the Control of Illicit Abuse and Distribution of Narcotics, Psychotropic, Precursors and other Addictive Substances

Download (168)

View PDF (185)

HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis

World Health Organization WHO (2020) C_WHO

WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches. HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i... more

Download (187)

View PDF (307)

Time to Act. Pragmatic and concrete actions for prevention of non-medical use of controlled substances, treatment of drug use disorders, social protection and health care for people affected

United Nations Office on Drug and Crime UNODC (2019) CC

UNGASS 2016 OUTCOME IMPLEMENTATION

Download (536)

View PDF (732)

Lesotho: DRUGS OF ABUSE ACT OF 2008

Parliament of Lesotho (2008) C2

An Act to repeal the Dangerous Medicines Act of 1973,to ensure the availability of certain drugs for exclusive medical, scientific and related purposes, while preventing their abuse; to prevent the diversion from lawful trade of controlled chemicals, controlled equipment and controlled materials for... more

Download (405)

View PDF (783)

Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies

Alipanah N, Jarlsberg L et al. (2018) CC

We systematically reviewed Medline as well as the references of published review articles for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-resistant TB through February 3, 2018. We included randomized controlled trials (RCTs) as well as prospective and retro... more

Download (436)

View PDF (614)

Controlled Substances Dispensing Record Form

Ecumenical Pharmaceutical Network (EPN) (2011) C2

Last revised 2015. Original Word document on: http://www.epnetwork.org/Resources/Standard%20Operating%20Procedure/Controlled%20substances%20dispensing%20record_Form.doc

Download (1527)

View PDF (2359)

The World Medcines situation 2011 Rational use of Medicines

World Health Organization WHO (2011) C_WHO

Millennium Development Goal 8E aims for affordable access to essential medicines. Essential medicines, as defined by WHO, are those that “satisfy the health-care needs of the majority of the population” and that should therefore “be available at all times in adequate amounts”. However, there... more

Download (623)

View PDF (1351)

Guidelines for surveillance of drug resistance in tuberculosis

World Health Organization (2021) C_WHO

6th edition

Download (2938)

View PDF (1148)

GUIDELINES FOR GOOD CLINICAL TRIAL PRACTICE IN ZIMBABWE

Medicines Control Authority of Zimbabwe (MCAZ) (2012) C2

Download (850)

View PDF (2842)

Nepal: Drugs Act, 2035, (1978)

World Health Organisation (WHO) (2000) C_WHO

Download (63)

View PDF (98)

Preventing the Spread of an Infectious Disease

Wolters Kluwer; Clinical Drug Information, Inc. and its affiliates andor licensors (2020) C2

Diseases that spread easily have always been around. Sometimes these diseases spread from one person to another person. Sometimes they spread from animals to people. Other times, they spread through germs in the water, soil, food, or air. Some diseases can be prevented or controlled with a vaccinat... more

Download (69)

View PDF (797)

A living WHO guideline on drugs for covid-19
recommended

Rochweg, B.; et al. (2021) CC

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379 Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE... more

Download (136)

View PDF (173)

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map

Van Katwyk, S. R.; Grimshaw, J. M.; et al (2019) C2

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc...e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. more

Download (114)

View PDF (153)

Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial

Pohlig G, Bernhard SC, Blum J, Burri C, Mpanya A, et al. PLOS Neclected Tropical Diseases (2016) CC

This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita... more

Download (119)

View PDF (147)

Access to controlled medicines for pain management in the WHO South-East Asia Region

World Health Organisation (WHO) (2023) C_WHO

The availability of controlled medicines is crucial for patients requiring palliative care, pain relief and symptom management. Many individuals worldwide, especially in low- and middle-income countries, continue to experience limited access to these essential medicines. Enhancing access to controll... more

Download (19)

View PDF (18)

Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society – 2021 update

Lalloo, U.G.; Kalla, I.S.; Abdool-Gaffar, S. et al. African Journal of Thoracic and Critical Care Medicine (2021) CC

sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapted to in-country realities are important to support ... more

Download (11)

View PDF (4)

Mindfulness meditation improves emotion regulation and reduces drug abuse

Tang, Y.Y.; Tang, R.; Posner, M.I. Drug and Alcohol Dependence (2016) CC

Background The core clinical symptoms of addiction include an enhanced incentive for drug taking (craving), impaired self-control (impulsivity and compulsivity), emotional dysregulation (negative mood) and increased stress reactivity. Symptoms related to impaired self-control involve reduced activi... more

A living WHO guideline on drugs for covid-19 recommended

A living WHO guideline on drugs for covid-19
recommended